Feedback / Questions
ABS-101 - Absci Corp
https://www.globenewswire.com/news-release/2025/05/13/3080609/0/en/Absci-Announces-First-Participants-Dosed-in-Phase-1-Clinical-Trial-of-ABS-101-a-Potential-Best-In-Class-anti-TL1A-Antibody-for-the-Treatment-of-Inflammatory-Bowel-Disease.html
May 13, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next